Positive reaction to Sudanese reporting campaign

Around the world / 07 May 2019

Photos: M Mohammed & W Elfil, NMPB

Up until a year ago Sudan had sent in only a handful of reports to VigiBase. Now it is working to clear a backlog of reports after a pharmacovigilance campaign went viral.


Sudan has been a member of the WHO Programme for International Drug Monitoring since 2008. But in common with many other countries, pharmacovigilance was low on its list of priorities before the third WHO Global Patient Safety Challenge: Medication Without Harm, put it firmly on the health­care agenda. In line with the international push to halve medication errors in five years, Sudan’s national pharmacovigilance centre has redoubled its efforts to promote medi­cines safety and provide training to health­care staff in reporting adverse drug reactions.

Since the beginning of 2018, a nationwide campaign to raise public awareness of the importance of reporting side effects from medicines has run in local newspapers, radio, television, and social media. A hotline dedicated to reporting adverse drug reactions and quality defects was launched, and hundreds of people flocked to public parks to watch free open-air comedy shows put on by pharmacists. The shows explored the wide range of unexpected adverse effects that may arise from prescribed medicines, self-medication and traditional medicines, and how they may be prevented by sharing information and reporting.  

Reporting forms with explanatory notes have been sent to hospitals for visitors and staff to complete and drop into boxes at designated collection points. A reporting app is also in the works, as 80% of the Sudanese population has smartphones and the country’s internet network coverage is excellent. Scanned reports can even be sent in via social media.

“103 reports were uploaded in 2018, and approximately double that number now await processing.”
Special boxes for the public and professionals to drop completed ADR reports.

Special boxes for the public and professionals to drop completed ADR reports.

The public campaign included free, open air stand-up comedy theatres, to encourage public awareness.

The public campaign included free, open air stand-up comedy theatres, to encourage public awareness.

Guidelines for training hospital and medicines information centres’ personnel in detecting and reporting adverse drug reactions are based on WHO best practices and the Guideline on Good Pharmacovigilance Practices for Arab Countries. Staff at 50 hospitals in Khartoum have already received coaching and other states are set to follow, with pharmacovigilance workshops for medicines information staff taking place nationwide. A similar system to the one used by the Yellow Card Scheme and medicines information centres in the UK is currently under development and would see medicines information centres collate and send reports to the national pharmacovigilance centre.

In just over a year, Sudanese centre has gone from submitting only a handful of reports to VigiBase, the WHO global database of individual case safety reports, to more reports than it can handle. It uploaded 103 reports in 2018, and approximately double that number now await processing. The centre is now looking at expanding the advisory committee of clinicians, pharmacists and pharmacoepidemiologists who review adverse drug reaction reports before they are shared with VigiBase to clear the backlog of reports awaiting assessment.

Khalid M Fadoul
Pharmacovigilance Lead, National Medicines & Poisons Board, Sudan

Ammar Abbas
Medicines Information & Medicines Management Pharmacist, Countess of Chester Hospital NHS Foundation Trust, UK

You may also like


EMA module on pregnancy prevention programmes and other pregnancy-specific risk minimisation

EMA has launched a public consultation on a new guidance: the EU-GVP Module XVI ADD III on pregnancy and other pregnancy-specific risk minimisation.

Around the world / 29 April 2022

Evolution of pharmacovigilance in the Kingdom of Eswatini

Eswatini may be a small country, but its National Pharmacovigilance Centre has big ambitions that, with support from the PAVIA project, are quickly translating into achievements.

Around the world / 04 February 2022

Developing a pharmacovigilance system in the Instituto Nacional de Cardiología Ignacio Chávez at Mexico City

Undaunted by the pandemic, the team at Instituto Nacional de Cardiología Ignacio Chávez (Mexico) established a PV centre and a follow-up unit with direct, daily clinical impact.

Around the world / 10 February 2022

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies.

Find out more